Simultaneous targeting of FcgRs and FcaRI enhances tumor cell killing

Cancer Immunology Research

Volumn 3, Issue 12, 2015, Pages 1316-1324

  Brandsma, Arianne M ^a   Broeke, Toine Ten ^a   Nederend, Maaike ^a   Meulenbroek, Laura A P M ^a   Van Tetering, Geert ^a   Meyer, Saskia ^a   Jansen, J H Marco ^a   Buitrago, M Alejandra Beltrán ^a   Nagelkerke, Sietse Q ^b   Németh, István ^c   Ubink, Ruud ^d   Rouwendal, Gerard ^d   Lohse, Stefan ^e   Valerius, Thomas ^e   Leusen, Jeanette H W ^a   Boross, Peter ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c GEDEON RICHTER LTD   (Hungary)

^d SYNTHON BV   (Netherlands)

^e UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; FC RECEPTOR IIA; FC RECEPTOR RI; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBB2 PROTEIN, HUMAN; FC(ALPHA) RECEPTOR; LEUKOCYTE ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL POPULATION; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG CYTOTOXICITY; DRUG SUBSTITUTION; FEMALE; HUMAN; HUMAN CELL; LEUKOCYTE; MOUSE; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMORPHONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR CELL DESTRUCTION; TUMOR XENOGRAFT; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BIOSYNTHESIS; DRUG SCREENING; IMMUNOLOGY; IMMUNOTHERAPY; NEUTROPHIL; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CETUXIMAB; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOTHERAPY; MICE; NEOPLASMS; NEUTROPHILS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, FC; RECEPTORS, IGG; TRASTUZUMAB; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84962204071     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0099-T     Document Type: Article

References (33)

1. Kim R. Cetuximab and panitumumab: Are they interchangeable? Lancet Oncol 2009; 10: 1140-1.
2. Bleeker WK, Lammerts van Bueren JJ, vanOjik HH,Gerritsen AF, Pluyter M, Houtkamp M, et al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. JImmunol 2004; 173: 4699-707.
3. Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 2012; 16: 15-31.
4. Klapper LN, Waterman H, Sela M, Yarden Y. Tumor-inhibitory antibodies to HER-2/ErbB-2may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res 2000; 60: 3384-8.
5. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC- 0941. Cancer Cell 2009; 15: 429-40.
6. Galizia G, Lieto E, De VF, Orditura M, Castellano P, Troiani T, et al. Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene 2007; 26: 3654-60.
7. Peipp M, Schneider-Merck T, Dechant M, Beyer T, van Bueren JJ, Bleeker WK, et al. Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutations. J Immunol 2008; 180: 4338-45.
8. Overdijk MB, Verploegen S, van den Brakel JH, Lammerts van Bueren JJ, Vink T, van de Winkel JG, et al. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. J Immunol 2011; 187: 3383-90.
9. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, et al. Trastuzumab-based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 2006; 94: 259-67.
10. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6: 443-6.
11. Beurskens FJ, Lindorfer MA, Farooqui M, Beum PV, Engelberts P, Mackus WJ, et al. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J Immunol 2012; 188: 3532-41.
12. PeippM, Lammerts van Bueren JJ, Schneider-Merck T, BleekerWW, Dechant M, Beyer T, et al. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 2008; 112: 2390-9.
13. Derer S, Glorius P, Schlaeth M, Lohse S, Klausz K, Muchhal U, et al. Increasing FcgammaRIIa affinity of an FcgammaRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity. MAbs 2014; 6: 409-21.
14. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009; 113: 3716-25.
15. Dechant M, Beyer T, Schneider-Merck T, Weisner W, Peipp M, van de Winkel JG, et al. Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor. J Immunol 2007; 179: 2936-43.
16. Boross P, Lohse S,NederendM, Jansen JH, van TeteringG,DechantM, et al. IgA EGFR antibodies mediate tumour killing in vivo. EMBO Mol Med 2013; 5: 1213-26.
17. Lohse S, Brunke C, Derer S, Peipp M, Boross P, Kellner C, et al. Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages. J Biol Chem 2012; 287: 25139-50.
18. Otten MA, Rudolph E, Dechant M, Tuk CW, Reijmers RM, Beelen RH, et al. Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors. J Immunol 2005; 174: 5472-80.
19. Kimple RJ, Vaseva AV, Cox AD, Baerman KM, Calvo BF, Tepper JE, et al. Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status. Clin Cancer Res 2010; 16: 912-23.
20. Hirsch FR, Varella-Garcia M, Cappuzzo F. Predictive value of EGFR and HER2 overexpression in advanced non-small cell lung cancer. Oncogene 2009; 28 Suppl 1: S32-S37.
21. Suo Z, Risberg B, Kalsson MG, Willman K, Tierens A, Skovlund E, et al. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 2002; 196: 17-25.
22. Larbouret C, Robert B, Navarro-Teulon I, Thezenas S, Ladjemi MZ, Morisseau S, et al. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res 2007; 13: 3356-62.
23. Maron R, Schechter B, Mancini M, Mahlknecht G, Yarden Y, Sela M. Inhibition of pancreatic carcinoma by homo- And heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2. Proc Natl Acad Sci U S A 2013; 110: 15389-94.
24. Beyer T, Lohse S, Berger S, Peipp M, Valerius T, Dechant M. Serum-free production and purification of chimeric IgA antibodies. J Immunol Methods 2009; 346: 26-37.
25. Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med 2006; 203: 743-53.
26. Bakema JE, Ganzevles SH, Fluitsma DM, Schilham MW, Beelen RH, Valerius T, et al. Targeting FcalphaRI on polymorphonuclear cells induces tumor cell killing through autophagy. J Immunol 2011; 187: 726-32.
27. Flinsenberg TW, Janssen WJ,Herczenik E, Boross P,NederendM, Jongeneel LH, et al. A novel FcgammaRIIa Q27W gene variant is associated with common variable immune deficiency through defective FcgammaRIIa downstream signaling. Clin Immunol 2014; 155: 108-17.
28. Bhatnagar N, Ahmad F, Hong HS, Eberhard J, Lu IN, Ballmaier M, et al. FcgammaRIII (CD16)-mediated ADCC by NK cells is regulated by monocytes and FcgammaRII (CD32). Eur J Immunol 2014; 44: 3368-79.
29. Kellner C, Derer S, Valerius T, PeippM. BoostingADCCandCDCactivity by Fc engineering and evaluation of antibody effector functions. Methods 2014; 65: 105-13.
30. van der Heijden J, Nagelkerke S, Zhao X, Geissler J, Rispens T, van den Berg TK, et al. Haplotypes of FcgammaRIIa and FcgammaRIIIb polymorphic variants influence IgG-mediated responses in neutrophils. J Immunol 2014; 192: 2715-21.
31. Horner H, Frank C, Dechant C, Repp R, Glennie M, Herrmann M, et al. Intimate cell conjugate formation and exchange of membrane lipids precede apoptosis induction in target cells during antibody-dependent, granulocyte-mediated cytotoxicity. J Immunol 2007; 179: 337-45.
32. Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther 2008; 7: 2517-27.
33. Albanesi M, Mancardi DA, Jonsson F, Iannascoli B, Fiette L, Di Santo JP, et al. Neutrophils mediate antibody-induced antitumor effects in mice. Blood 2013; 122: 3160-4.